Articles Vol. 67 No. CĐ2-NCKH 05/03/2026

CHARACTERISTICS OF SLEEP DISORDERS IN PLAQUE PSORIASIS PATIENTS TREATED WITH BIOLOGICS AT BACH MAI HOSPITAL

Tran Thai` Sơn1,2, Bui Van Loi3,4, Nguyen Thi Thu Hien1,2, Pham Thi Giang1,2, Tran Thi Tinh1,2, Nguyen Thi Ngoc Anh1,2, Tran Thi Quyen1,2
1 Department of Dermatology and Burns, Bach Mai Hospital
2 Khoa Da liễu và Bỏng, Bệnh viện Bạch Mai
3 Institute of Mental Health, Bach Mai Hospital
4 Viện Sức khỏe Tâm thần, Bệnh viện Bạch Mai
DOI: 10.52163/yhc.v67iCD2.4454
17 Views
26 Downloads
Keywords
Psoriasis, biologics, sleep disorders, PSQI, PASI, PNRS.
Abstract

Objective: To describe the characteristics of sleep disorders and related factors in patients with plaque psoriasis undergoing maintenance treatment with biologics at Bach Mai Hospital.

Methods: A cross-sectional descriptive study was conducted on 62 patients with plaque psoriasis receiving outpatient treatment with biologics (including Secukinumab, Ustekinumab, and Guselkumab) at Bach Mai Hospital from January 2025 to November 2025. Sleep quality was assessed using the PSQI, disease severity was evaluated using the PASI, and itch intensity was measured using the PNRS.

Results: The mean age of the study group was 46.5 ± 12.4 years, with 82.3% of patients treated with Secukinumab. The mean PASI score was low (2.8 ± 3.1). The mean PSQI score was 5.8 ± 3.4. The prevalence of sleep disorders (PSQI > 5) was 43.5%. The most common disturbances were short actual sleep duration (5.9 ± 1.4 hours/night) and difficulty falling asleep (sleep latency). There was a moderate positive correlation between itch score (PNRS) and PSQI score (r = 0.45; p = 0.001). No statistically significant correlation was found between the PASI score and sleep quality (p > 0.05).

Conclusion: Although biologics provide effective control of skin lesions, a significant proportion of patients still experience sleep disorders. Itch severity is the primary factor affecting sleep quality rather than the degree of skin clearance.

References
[1]
Mehta S, Sathe N.C. Plaque Psoriasis. In: StatPearls. StatPearls Publishing, 2025. Accessed December 15, 2025. http://www.ncbi.nlm.nih.gov/books/NBK430879/ Google Scholar
[2]
Leung A, Haran K, Marquez-Grap G et al. The impact of psoriasis on sleep quality: examining the relationship between psoriasis, sleep, and mental health. Dermatol Ther, 2025, 15 (8): 2247-2254. doi: 10.1007/s13555-025-01449-4. Google Scholar
[3]
Psoriasis Area and Severity Index - an overview. ScienceDirect Topics. Accessed December 15, 2025. https://www.sciencedirect.com/topics/medicine-and-dentistry/psoriasis-area-and-severity-index. Google Scholar
[4]
Buysse D.J, Reynolds C.F, Monk T.H, Berman S.R, Kupfer D.J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res, 1989, 28 (2): 193-213. doi: 10.1016/0165-1781(89)90047-4. Google Scholar
[5]
Gupta M.A, Simpson F.C, Gupta A.K. Psoriasis and sleep disorders: A systematic review. Sleep Med Rev, 2016, 29: 63-75. doi: 10.1016/j.smrv.2015.09.003. Google Scholar
[6]
Strober B.E, Sobell J.M, Duffin K.C et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol, 2012, 167 (6): 1374-1381. doi: 10.1111/bjd.12000. Google Scholar
[7]
Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis: a case-controlled study. Br J Dermatol, 2018, 179 (6): 1376-1384. doi: 10.1111/bjd.16702. Google Scholar